Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone Palmitate 6-Month Extension Study
NCT04072575Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2019
- Primary completion
- May 2022
- Modality
- Metabolically Activated Prodrugs
- Countries
- 6
01
Overview
A Phase 3 trial of paliperidone palmitate in schizophrenia, sponsored by Janssen Pharmaceutical. Started Sep 2019; status: completed.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04072575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04072575.